TD Cowen upgraded UnitedHealth to buy from hold and raised its price target to $455 from $402, implying 38% upside. Analyst Ryan Langston expects the company to deliver mid-to-high-teens earnings-per-share growth through at least 2028, driven by an Optum Health recovery and improvements in its Medicare Advantage and Medicaid businesses. The stock has fallen 14% over the past three months amid regulatory uncertainty over anti-fraud measures in Medicare. Langston said these headwinds should not derail Optum Health’s continued margin expansion, while external growth at Optum Rx and the commercialization of Optum Insight’s artificial intelligence products remain areas to watch. The call aligns with Wall Street consensus: 25 of the 28 analysts covering UnitedHealth rate the stock a buy or strong buy.
Source: Read the original article


